|
1
|
Puri S and Asotra S: Primary vaginal
malignant melanoma: A rare entity with review of literature. J
Cancer Res Ther. 15:1392–1394. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang HY, Wu XY, Zhang X, Yang XH, Long YK,
Feng YF and Wang F: Prevalence of NRAS mutation, PD-L1 expression
and amplification, and overall survival analysis in 36 primary
vaginal melanomas. Oncologist. 25:e291–e301. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta D, Malpica A, Deavers MT and Silva
EG: Vaginal melanoma: A clinicopathologic and immunohistochemical
study of 26 cases. Am J Surg Pathol. 26:1450–1457. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Piura B: Management of primary melanoma of
the female urogenital tract. Lancet Oncol. 9:973–981. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Terzakis E, Androutsopoulos G, Adonakis G,
Zygouris D, Grigoriadis C and Decavalas G: Vaginal primary
malignant melanoma: Report of four cases and review of the
literature. Eur J Gynaecol Oncol. 32:122–124. 2011.PubMed/NCBI
|
|
6
|
Guo N and Zhang J: Primary vaginal
malignant melanoma: A rare case report of successful treatment with
nivolumab. Medicine (Baltimore). 100:e256912021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Frumovitz M, Etchepareborda M, Sun CC,
Soliman PT, Eifel PJ, Levenback CF and Ramirez PT: Primary
malignant melanoma of the vagina. Obstet Gynecol. 116:1358–1365.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takahashi J and Nagasawa S:
Immunostimulatory effects of radiotherapy for local and systemic
control of melanoma: A review. Int J Mol Sci. 21:93242020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fukumura D, Kloepper J, Amoozgar Z, Duda
DG and Jain RK: Enhancing cancer immunotherapy using
antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol.
15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie Y, Chen Z, Zhong Q, Chen Y, Shangguan
W and Xie W: Efficacy and safety of immunological checkpoint
inhibitors combined with anti-angiogenic drugs in first-line
treatment of metastatic renal cell carcinoma: A systematic review
and meta-analysis. Transl Androl Urol. 10:300–309. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee WS, Yang H, Chon HJ and Kim C:
Combination of anti-angiogenic therapy and immune checkpoint
blockade normalizes vascular-immune crosstalk to potentiate cancer
immunity. Exp Mol Med. 52:1475–1485. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goedegebuure RSA, de Klerk LK, Bass AJ,
Derks S and Thijssen VLJL: Combining radiotherapy with
anti-angiogenic therapy and immunotherapy; a therapeutic triad for
cancer? Front Immunol. 9:31072019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hack SP, Zhu AX and Wang Y: Augmenting
anticancer immunity through combined targeting of angiogenic and
PD-1/PD-L1 pathways: Challenges and opportunities. Front Immunol.
11:5988772020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang B, Yan X, Sheng X, Si L, Cui C, Kong
Y, Mao L, Lian B, Bai X, Wang X, et al: Safety and clinical
activity with an anti-PD-1 antibody JS001 in advanced melanoma or
urologic cancer patients. J Hematol Oncol. 12:72019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Dong Y, Kong L, Shi F, Zhu H and Yu
J: Abscopal effect of radiotherapy combined with immune checkpoint
inhibitors. J Hematol Oncol. 11:1042018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao X and Shao C: Radiotherapy-mediated
immunomodulation and anti-tumor abscopal effect combining immune
checkpoint blockade. Cancers (Basel). 12:27622020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ngwa W, Irabor OC, Schoenfeld JD, Hesser
J, Demaria S and Formenti SC: Using immunotherapy to boost the
abscopal effect. Nat Rev Cancer. 18:313–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stamell EF, Wolchok JD, Gnjatic S, Lee NY
and Brownell I: The abscopal effect associated with a systemic
anti-melanoma immune response. Int J Radiat Oncol Biol Phys.
85:293–295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rogers SJ, Puric E, Eberle B, Datta NR and
Bodis SB: Radiotherapy for melanoma: More than DNA damage. Dermatol
Res Pract. 2019:94353892019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hendrickx A, Cozzio A, Plasswilm L and
Panje CM: Radiotherapy for lentigo maligna and lentigo maligna
melanoma-a systematic review. Radiat Oncol. 15:1742020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hodge JW, Sharp HJ and Gameiro SR:
Abscopal regression of antigen disparate tumors by antigen cascade
after systemic tumor vaccination in combination with local tumor
radiation. Cancer Biother Radiopharm. 27:12–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Demaria S, Kawashima N, Yang AM, Devitt
ML, Babb JS, Allison JP and Formenti SC: Immune-mediated inhibition
of metastases after treatment with local radiation and CTLA-4
blockade in a mouse model of breast cancer. Clin Cancer Res.
11:728–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vatner RE, Cooper BT, Vanpouille-Box C,
Demaria S and Formenti SC: Combinations of immunotherapy and
radiation in cancer therapy. Front Oncol. 4:3252014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Twyman-Saint Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan Z, Fromm A, Ahmed KA, Grass GD, Yang
GQ, Oliver DE, Dilling TJ, Antonia SJ and Perez BA: Radiotherapy
rescue of a nivolumab-refractory immune response in a patient with
PD-L1-negative metastatic squamous cell carcinoma of the lung. J
Thorac Oncol. 12:e135–e136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Komatsu T, Nakamura K and Kawase A:
Abscopal effect of nivolumab in a patient with primary lung cancer.
J Thorac Oncol. 12:e143–e144. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T,
Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S,
et al: Real-world efficacy of anti-PD-1 antibody or combined
anti-PD-1 plus anti-CTLA-4 antibodies, with or without
radiotherapy, in advanced mucosal melanoma patients: A
retrospective, multicenter study. Eur J Cancer. 157:361–372. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chicas-Sett R, Morales-Orue I,
Rodriguez-Abreu D and Lara-Jimenez P: Combining radiotherapy and
ipilimumab induces clinically relevant radiation-induced abscopal
effects in metastatic melanoma patients: A systematic review. Clin
Transl Radiat Oncol. 9:5–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Moya-Plana A, Herrera Gómez RG, Rossoni C,
Dercle L, Ammari S, Girault I, Roy S, Scoazec JY, Vagner S, Janot
F, et al: Evaluation of the efficacy of immunotherapy for
non-resectable mucosal melanoma. Cancer Immunol Immunother.
68:1171–1178. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Indini A, Di Guardo L, Cimminiello C,
Lorusso D, Raspagliesi F and Del Vecchio M: Investigating the role
of immunotherapy in advanced/recurrent female genital tract
melanoma: A preliminary experience. J Gynecol Oncol. 30:e942019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reynders K, Illidge T, Siva S, Chang JY
and De Ruysscher D: The abscopal effect of local radiotherapy:
Using immunotherapy to make a rare event clinically relevant.
Cancer Treat Rev. 41:503–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Z, Zhao Q, Zheng Z, Liu S, Meng L,
Dong L and Jiang X: Vascular normalization in immunotherapy: A
promising mechanisms combined with radiotherapy. Biomed
Pharmacother. 139:1116072021. View Article : Google Scholar : PubMed/NCBI
|
